Literature DB >> 11732711

Hippocampal dysfunction in schizophrenia.

N A Schmajuk1.   

Abstract

Although not necessarily primary to the disease, hippocampal dysfunction in schizophrenia is suggested by morphological changes in the hippocampal formation reported in schizophrenic patients. This notion receives additional support from studies showing that 1) similar behavioral deficits are exhibited by both schizophrenics and animals with hippocampal lesions, and 2) some of these behavioral deficits are reversed by neuroleptics in both schizophrenics and lesioned animals. A brain-mapped neural network model is used to explain how some impairments in attention can be caused by hippocampal dysfunction and ameliorated by dopaminergic blockers.

Entities:  

Mesh:

Year:  2001        PMID: 11732711     DOI: 10.1002/hipo.1074

Source DB:  PubMed          Journal:  Hippocampus        ISSN: 1050-9631            Impact factor:   3.899


  11 in total

Review 1.  The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications.

Authors:  Paul J Harrison
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

Review 2.  Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.

Authors:  Mason M Silveira; Jonathon C Arnold; Steven R Laviolette; Cecilia J Hillard; Marta Celorrio; María S Aymerich; Wendy K Adams
Journal:  Neurosci Biobehav Rev       Date:  2016-09-14       Impact factor: 8.989

3.  Fornix integrity and hippocampal volume in male schizophrenic patients.

Authors:  Noriomi Kuroki; Marek Kubicki; Paul G Nestor; Dean F Salisbury; Hae-Jeong Park; James J Levitt; Sophie Woolston; Melissa Frumin; Margaret Niznikiewicz; Carl-Fredrik Westin; Stephan E Maier; Robert W McCarley; Martha E Shenton
Journal:  Biol Psychiatry       Date:  2006-01-10       Impact factor: 13.382

4.  Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats.

Authors:  Jean-Charles Paterna; Joram Feldon; Hansruedi Büeler
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

5.  Risperidone and haloperidol promote survival of stem cells in the rat hippocampus.

Authors:  Gerburg Keilhoff; Gisela Grecksch; Hans-Gert Bernstein; Thomas Roskoden; Axel Becker
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-05       Impact factor: 5.270

6.  Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia.

Authors:  Konrad Talbot; Wess L Eidem; Caroline L Tinsley; Matthew A Benson; Edward W Thompson; Rachel J Smith; Chang-Gyu Hahn; Steven J Siegel; John Q Trojanowski; Raquel E Gur; Derek J Blake; Steven E Arnold
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

7.  Genetic influences on hippocampal structure and function in recombinant inbred mice.

Authors:  Maureen V Martin; James D Churchill; Hongxin Dong; David F Wozniak; James M Cheverud; John G Csernansky
Journal:  Behav Brain Res       Date:  2008-08-05       Impact factor: 3.332

8.  Hippocampi, thalami, and accumbens microstructural damage in schizophrenia: a volumetry, diffusivity, and neuropsychological study.

Authors:  Ilaria Spoletini; Andrea Cherubini; Giulia Banfi; Ivo Alex Rubino; Patrice Peran; Carlo Caltagirone; Gianfranco Spalletta
Journal:  Schizophr Bull       Date:  2009-06-19       Impact factor: 9.306

9.  Aberrant Effective Connectivity in Schizophrenia Patients during Appetitive Conditioning.

Authors:  Andreea Oliviana Diaconescu; Jimmy Jensen; Hongye Wang; Matthäus Willeit; Mahesh Menon; Shitij Kapur; Anthony R McIntosh
Journal:  Front Hum Neurosci       Date:  2011-01-17       Impact factor: 3.169

10.  Neonatal bilateral lidocaine administration into the ventral hippocampus caused postpubertal behavioral changes: An animal model of neurodevelopmental psychopathological disorders.

Authors:  Vanessa Blas-Valdivia; Edgar Cano-Europa; Adelaida Hernández-García; Rocio Ortiz-Butrón
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.